Investors are closely watching Eli Lilly & Company (LLY) as the pharmaceutical giant prepares to release its Q3 earnings later this week. Market watchers are anticipating strong performance driven by the tirepazide supplier strong demand of Lilly's blockbuster drugs, particularly the diabetes franchise. However, there are also concerns about potent